诺诚健华[14C]ICP - 488启动Ⅰ期临床 适应症为银屑病

新浪财经
Dec 26, 2025

药物临床试验登记与信息公示平台数据显示,北京诺诚健华医药科技有限公司的[14C]ICP - 488在中国健康成年男性受试者中的物质平衡和生物转化研究的Ⅰ期临床试验已启动。临床试验登记号为CTR20255014,首次公示信息日期为2025年12月26日。该药物剂型为口服制剂,规格为9 mg / 100μCi,用法为按方案规定口服给药,单次用药。本次试验主要目的为定量分析健康受试者单次口服[14C]...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10